Volume 64, Issue 1 pp. 90-94
CLINICAL RESEARCH SHORT REPORT

Assessment of clinical factors affecting outcome of myasthenia gravis

Yukiyo Yoshimoto MD

Yukiyo Yoshimoto MD

Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Search for more papers by this author
Shimon Ishida MD, PhD

Shimon Ishida MD, PhD

Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Search for more papers by this author
Takafumi Hosokawa MD, PhD

Takafumi Hosokawa MD, PhD

Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Search for more papers by this author
Shigeki Arawaka MD, PhD

Corresponding Author

Shigeki Arawaka MD, PhD

Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Correspondence

Shigeki Arawaka, Division of Neurology, Department of Internal Medicine IV, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan.

Email: [email protected]

Search for more papers by this author
First published: 22 April 2021
Citations: 3

Funding information: Osaka Medical College; Myasthenia Gravis Foundation of America

Abstract

Introduction/Aims

In myasthenia gravis (MG) therapy, achieving Myasthenia Gravis Foundation of America minimal manifestation (MM) or better status is proposed as a desirable target. However, this level of control is often not achieved and clinical factors affecting prognosis remain unclear.

Methods

Participants were 104 consecutive patients with MG who visited Osaka Medical College Hospital. We retrospectively assessed the association of clinical and laboratory features at baseline with prognosis. Eighty patients who achieved MM or better status were classified as the good outcome group and the remaining 24 patients were classified as the poor outcome group.

Results

The rate of dysphagia at baseline was significantly higher in the poor outcome group than in the good outcome group (P = .002). The levels of serum total protein and albumin at baseline were both significantly lower in the poor outcome group than in the good outcome group (P = .036 and P = .014, respectively). In addition, Controlling Nutritional Status scores at baseline were significantly higher in the poor outcome group than in the good outcome group (P = .043). Multivariate analysis using a Cox proportional hazards model showed that dysphagia (hazard ratio [HR], 6.92; 95% confidence interval [CI], 1.49-40.31) and hypoalbuminemia (HR, 2.57; 95% CI, 1.04-6.57) at baseline were risk factors that predicted prognosis.

Discussion

These findings suggest that dysphagia and hypoalbuminemia at baseline are associated with outcomes and are predictive risk factors for poorer outcomes in patients with MG.

CONFLICT OF INTEREST

None of the authors has any conflict of interest to disclose.

DATA AVAILABILITY STATEMENT

Data available on request from the authors

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me